Monoaminergic Network Dysfunction and Development of Depression in Multiple Sclerosis: a Longitudinal Investigation

Overview

Journal J Neurol

Specialty Neurology

Date 2023 Dec 19

PMID 38112782

Authors

Damiano Mistri

Paola Valsasina

Loredana Storelli

Massimo Filippi

Maria A Rocca

Affiliations

Soon will be listed here.

Abstract

Background: Monoaminergic network dysfunction is thought to underpin depression in multiple sclerosis (MS) patients. However, longitudinal studies are lacking.

Objectives: Here, we investigated the association between development of depressive symptoms in MS and changes of resting-state functional connectivity (RS FC) within monoaminergic networks.

Methods: Forty-nine MS patients without depression [Montgomery-Asberg Depression Scale (MADRS) ≤ 9] and 27 healthy controls underwent clinical and 3.0 T RS FC assessment at baseline and after a median follow-up of 1.6 years (interquartile range 1.0-2.1 years). Monoamine-related RS FC was derived by independent component analysis, constrained to PET atlases for dopamine, noradrenaline and serotonin transporters. Longitudinal changes of RS FC within monoaminergic networks and their correlations with MADRS scores were assessed.

Results: At baseline, MS patients showed decreased RS FC vs healthy controls in all PET-guided monoaminergic networks in frontal, cingulate and cerebellar cortices, and increased RS FC in parieto-occipital regions. Fourteen (29%) MS patients developed depressive symptoms (MADRS > 9) at follow-up (D-MS) and exhibited widespread RS FC decrease over time in the PET-guided dopamine network, mainly in orbitofrontal, occipital, anterior cingulate and precuneal cortices compared to patients who did not develop depressive symptoms. In D-MS, decreased RS FC over time was also observed in parahippocampal and occipital regions of the PET-guided noradrenaline network. Decreased RS FC over time in dopamine and noradrenaline PET-guided networks correlated with concomitant increased MADRS scores (r = range - 0.65/- 0.61, p < 0.001).

Conclusions: The development of depressive symptoms in MS patients was associated with specific RS FC changes within the dopamine and noradrenaline networks.

Citing Articles

Causal relationships of grey matter structures in multiple sclerosis and neuromyelitis optica spectrum disorder: insights from Mendelian randomization.

Sun J, Xie Y, Li T, Zhao Y, Zhao W, Yu Z Brain Commun. 2024; 6(5):fcae308.

PMID: 39318784 PMC: 11420985. DOI: 10.1093/braincomms/fcae308.

Depression and anxiety in multiple sclerosis. Review of a fatal combination.

Jellinger K J Neural Transm (Vienna). 2024; 131(8):847-869.

PMID: 38869643 DOI: 10.1007/s00702-024-02792-0.

Neuroimaging and neuromodulation of invisible symptoms in multiple sclerosis.

Ayache S, Chalah M Front Hum Neurosci. 2024; 18:1376095.

PMID: 38454906 PMC: 10917909. DOI: 10.3389/fnhum.2024.1376095.

References

Feinstein A, Magalhaes S, Richard J, Audet B, Moore C . The link between multiple sclerosis and depression. Nat Rev Neurol. 2014; 10(9):507-17. DOI: 10.1038/nrneurol.2014.139. View

Solaro C, Gamberini G, Masuccio F . Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment. CNS Drugs. 2018; 32(2):117-133. DOI: 10.1007/s40263-018-0489-5. View

Riccelli R, Passamonti L, Cerasa A, Nigro S, Cavalli S, Chiriaco C . Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients. Mult Scler. 2015; 22(8):1094-105. DOI: 10.1177/1352458515606987. View

Rocca M, Pravata E, Valsasina P, Radaelli M, Colombo B, Vacchi L . Hippocampal-DMN disconnectivity in MS is related to WM lesions and depression. Hum Brain Mapp. 2015; 36(12):5051-63. PMC: 6869286. DOI: 10.1002/hbm.22992. View

Hamon M, Blier P . Monoamine neurocircuitry in depression and strategies for new treatments. Prog Neuropsychopharmacol Biol Psychiatry. 2013; 45:54-63. DOI: 10.1016/j.pnpbp.2013.04.009. View

Hesse S, Moeller F, Petroff D, Lobsien D, Luthardt J, Regenthal R . Altered serotonin transporter availability in patients with multiple sclerosis. Eur J Nucl Med Mol Imaging. 2014; 41(5):827-35. DOI: 10.1007/s00259-013-2636-z. View

Schmidt E, Schinke C, Rullmann M, Luthardt J, Becker G, Haars S . Changes of central noradrenaline transporter availability in immunotherapy-naïve multiple sclerosis patients. Sci Rep. 2020; 10(1):14651. PMC: 7474089. DOI: 10.1038/s41598-020-70732-5. View

Carotenuto A, Wilson H, Giordano B, Caminiti S, Chappell Z, Williams S . Impaired connectivity within neuromodulatory networks in multiple sclerosis and clinical implications. J Neurol. 2020; 267(7):2042-2053. PMC: 7320961. DOI: 10.1007/s00415-020-09806-3. View

Carotenuto A, Valsasina P, Preziosa P, Mistri D, Filippi M, Rocca M . Monoaminergic network abnormalities: a marker for multiple sclerosis-related fatigue and depression. J Neurol Neurosurg Psychiatry. 2022; 94(2):94-101. DOI: 10.1136/jnnp-2022-330109. View

10.

OLDFIELD R . The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971; 9(1):97-113. DOI: 10.1016/0028-3932(71)90067-4. View

11.

Kurtzke J . Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983; 33(11):1444-52. DOI: 10.1212/wnl.33.11.1444. View

12.

Hawley C, Gale T, Sivakumaran T . Defining remission by cut off score on the MADRS: selecting the optimal value. J Affect Disord. 2002; 72(2):177-84. DOI: 10.1016/s0165-0327(01)00451-7. View

13.

Marchesi O, Vizzino C, Meani A, Conti L, Riccitelli G, Preziosa P . Fatigue in multiple sclerosis patients with different clinical phenotypes: a clinical and magnetic resonance imaging study. Eur J Neurol. 2020; 27(12):2549-2560. DOI: 10.1111/ene.14471. View

14.

Amato M, Portaccio E, Goretti B, Zipoli V, Ricchiuti L, De Caro M . The Rao's Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population. Mult Scler. 2007; 12(6):787-93. DOI: 10.1177/1352458506070933. View

15.

Valverde S, Cabezas M, Roura E, Gonzalez-Villa S, Pareto D, Vilanova J . Improving automated multiple sclerosis lesion segmentation with a cascaded 3D convolutional neural network approach. Neuroimage. 2017; 155:159-168. DOI: 10.1016/j.neuroimage.2017.04.034. View

16.

Battaglini M, Jenkinson M, De Stefano N . Evaluating and reducing the impact of white matter lesions on brain volume measurements. Hum Brain Mapp. 2011; 33(9):2062-71. PMC: 6870255. DOI: 10.1002/hbm.21344. View

17.

Jenkinson M, Beckmann C, Behrens T, Woolrich M, Smith S . FSL. Neuroimage. 2011; 62(2):782-90. DOI: 10.1016/j.neuroimage.2011.09.015. View

18.

Krisponeit J, Fischer S, Esser S, Moshnyaga V, Schmidt T, Piper L . The morphology of VO/TiO(001): terraces, facets, and cracks. Sci Rep. 2020; 10(1):22374. PMC: 7758337. DOI: 10.1038/s41598-020-78584-9. View

19.

Carandini T, Cercignani M, Galimberti D, Scarpini E, Bozzali M . The distinct roles of monoamines in multiple sclerosis: A bridge between the immune and nervous systems?. Brain Behav Immun. 2021; 94:381-391. DOI: 10.1016/j.bbi.2021.02.030. View

20.

Polak P, Kalinin S, Feinstein D . Locus coeruleus damage and noradrenaline reductions in multiple sclerosis and experimental autoimmune encephalomyelitis. Brain. 2011; 134(Pt 3):665-77. PMC: 3105488. DOI: 10.1093/brain/awq362. View